NTB-928
Solid Tumors (FRα+)
Pre-clinicalActive
Key Facts
About 92Bio
92Bio is a private, preclinical-stage biotech focused on developing best-in-class multispecific T-cell engagers for oncology. Its lead program, NTB-928 (FRα x CD3), is slated for clinical entry in H1 2026, with a γδ T-cell engager for AML following in 2027. The company is backed by experienced venture capital investors and is headquartered in Hayward, California, with a culture emphasizing innovation, collaboration, and calculated risk-taking.
View full company profile